Randomized phase II trial in prostate cancer with hormone-sensitive OligometaSTatic relapse: Combining stereotactic ablative radiotherapy and durvalumab (POSTCARD GETUG P13): Study protocol

Background: As in other solid tumors, increasing evidence indicates that patients diagnosed with a limited number of prostate cancer metastases, so-called oligometastases, have a better prognosis than patients with extensive metastatic disease. Stereotactic body radiotherapy (SBRT) is now considered...

Popoln opis

Bibliografske podrobnosti

Principais autores:	Maximilien Rogé, Yoann Pointreau, Paul Sargos, Emmanuel Meyer, Ulrike Schick, Ali Hasbini, Emmanuel Rio, Guillaume Bera, Amandine Ruffier, Magali Quivrin, Mathieu Chasseray, Igor Latorzeff, Etienne Martin, Valentine Guimas, Pascal Pommier, Thomas Leroy, Philippe Ronchin, Alexis Lepinoy, Audrey Grand, Lysian Cartier, Ossama Didas, Fabrice Denis, Vincent Libois, Audrey Blanc-Lapierre, Stéphane Supiot
Format:	Artigo
Jezik:	Inglês
Izdano:	Elsevier 2023-05-01
Serija:	Clinical and Translational Radiation Oncology
Teme:	Prostate cancer Oligorecurrent Oligometastases Stereotactic body radiotherapy Immunotherapy
Online dostop:	http://www.sciencedirect.com/science/article/pii/S2405630823000381
Oznake:	Označite Brez oznak, prvi označite!